Skip to main content
Clinical Trials/JPRN-UMIN000010721
JPRN-UMIN000010721
Recruiting
Phase 2

Assessment of efficacy and safety of continouation maintenance therapy with gemcitabine after cisplatin-gemcitabine induction chemotherapy in advanced squamous cell lung cancer (KTORG1302) - Assessment of efficacy and safety of CDDP+GEM followed by GEM in advanced squamous cell lung cancer

Kyoto Thoracic Oncology Research Group (KTORG)0 sites60 target enrollmentMay 15, 2013

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
squamous cell lung cancer
Sponsor
Kyoto Thoracic Oncology Research Group (KTORG)
Enrollment
60
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 15, 2013
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Kyoto Thoracic Oncology Research Group (KTORG)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Patients with histologically proven non\-squamous cell lung cancer 2\) Recognized ILD or pulmonary fibrosis on X\-rays 3\) Pleural effusion, peritoneal fluid and pericardial fluid that need treatment 4\) Superior vena cava syndrome 5\) Symptomatic brain metastasis 6\) Active concomitant malignancy 7\) Prior therapy with gemcitabine 8\) Diabetes and hypertension that cannot be controlled 9\) Liver cirrhosis 10\) Symptomatic or asymptomatic but treated heart disease 11\) Severe infectious disease 12\) Pregnant women, possibly pregnant women, wishing to become pregnant 13\) Serious drug hypersensitivity or a history of drug allergy 14\) Refusal of supportive care such as blood transfusion 15\) Bleeding tendency 16\) Other conditions not suitable for this study

Outcomes

Primary Outcomes

Not specified

Similar Trials